Objective
Our previous studies have shown the presence of a high percentage of human papillomavirus (HPV) infection in the esophagus in the high-risk areas for esophageal cancer (EC) in China, where EC has been an endemic disease for generations. These data, being in alignment with the currently available evidence on the etiological role of HPV in the pathogenesis of squamous cell carcinomas at other mucosal sites, have implicated HPV as a potential etiological agent in human esophageal carcinogenesis as well. However, the previous studies have only included small numbers of biopies, well-organized and extensive epidemiological studies are urgently needed to assess the prevalence of esophageal HPV infections, and their association with esophageal carcinogenesis. During 1990-1992 our Chinese collaborators in Zhengzhou of China have collected a series of more than 2000 esophageal specimens derived from more than 700 patients suffering from a variety of esophageal squamous epithelial lesions, with pertinent clinical data available. Using multiple histopathological and DNA-detecting techniques which have been well established in our papillomavirus research laboratories in Kuopio of Finland and Heidelberg of Germany, such as light- and electron microscopy, immunohistochemistry, DNA in situ hybridization, Southern blot and dot blot hybridization, polymerase chain reaction, single strand conformation polymorphism, as well as viral isolating, cloning and DNA sequencing techniques, we are planning to systematically evaluate the prevalence of HPV infections in the high-risk area for EC in China, the associations of infectious agents (particularly HPV) with esophageal cancer, and the synergistic actions between HPV and other carcinogenic factors as well as infectious agents, e.g. HSV, CMV, EBV, and fungi. Meanwhile, the prognostic factors for EC will be also analyzed in Siena of Italy by using immunohistochemical cytokeratin staining and multiple histoquantitive methods. These systematic evaluations of EC in the high-risk area using modern pathological and biological techniques could certainly obtain valuable information on the etiology, pathogenesis and prognosis of EC, and therefore provide reliable experimental data for prevention and treatment of this fatal disease in the future.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics DNA
- medical and health sciences clinical medicine oncology skin cancer squamous cell carcinoma
- natural sciences physical sciences optics microscopy electron microscopy
- medical and health sciences clinical medicine oncology cervical cancer
- medical and health sciences health sciences infectious diseases DNA viruses
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
70211 Kuopio
Finland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.